MS: EMA Committee Supports Diroximel Fumarate Approval

MS: EMA Committee Supports Diroximel Fumarate Approval

Sep 17, 2021 | News, Regulatory

European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has announced their approval of diroximel fumarate (Vumerity, Biogen Inc) for adults diagnosed with relapsing-remitting multiple sclerosis (MS). Although Diroximel fumarate is...